Moreover, we investigated the molecular characteristics of GC tumors with PIK3CA mutations or MET amplifications, given that the treatment arms assigned by these biomarkers demonstrated the highest response rates in the VIKTORY trial.10 The gene discussed is PIK3CA; the disease is gastric cancer.